TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19945106

Group type: EXPERIMENTAL
Intervention: Calligraphy handwriting
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation and guided imagery training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 17828786

Group type: EXPERIMENTAL
Intervention: Long-acting oxybutynin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11986101

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 118
Study: 9561981

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study: 8282334

Group type: EXPERIMENTAL
Intervention: cilazapril (2.5 to 5 mg/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: atenolol (50 to 100 mg/d)
Number of subjects: 17
Study: 2498936

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine chewing gum
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine chewing gum
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 16
Study: 1156825

Group type: EXPERIMENTAL
Intervention: Patient education about psychiatric consultations
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 31041623

Group type: EXPERIMENTAL
Intervention: School support intervention for females
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: School support intervention for males
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: School support intervention
Number of subjects: 835
Study: 28917657

Group type: EXPERIMENTAL
Intervention: ATRA plus danazol (10 mg twice daily + 200 mg twice daily)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Danazol (200 mg twice daily)
Number of subjects: 93
Study: 25588847

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Proximal tibial plating (PTP)
Number of subjects: 58
Study: 23223674

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 30
Study: 21324455

Group type: EXPERIMENTAL
Intervention: Microdose leuprolide acetate (LA) protocol
Number of subjects: 54

Group type: COMPARATOR
Intervention: GnRH antagonist protocol with luteal phase E(2) patch
Number of subjects: 54
Study: 19243357

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg after fasting
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16954724

Group type: EXPERIMENTAL
Intervention: Zidovudine (oral and intravenous dosing)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Contraceptive therapy (oral or injectable)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Zidovudine (oral administration)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Contraceptive therapy
Number of subjects: 38
Study: 15159264

Group type: EXPERIMENTAL
Intervention: Subcutaneous adjusted-dose unfractionated heparin (UFH)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Fixed-dose low-molecular-weight heparin (nadroparin)
Number of subjects: 720
Study: 11566649

Group type: EXPERIMENTAL
Intervention: Red palm oil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sunflower oil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (traditional diet with dark-green leafy vegetables)
Number of subjects: 90
Study: 9032176

Group type: EXPERIMENTAL
Intervention: Segmental antigen challenge (SAC) on Days 1 and 2
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Segmental antigen challenge (SAC) on Day 2
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Eosinophil-active cytokines (IL-5, GM-CSF, IL-3)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 3
Study: 8344680

Group type: EXPERIMENTAL
Intervention: 3 i.v. cyclophosphamide pulses until remission
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 12 i.v. cyclophosphamide pulses
Number of subjects: 21
Study: 31435964

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of alfaxalone (10 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous injection of alfaxalone (10 mg/kg)
Number of subjects: 20
Study: 30109955

Group type: EXPERIMENTAL
Intervention: Family-based interventions promoting child sleep (20% of interventions)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Interventions targeting diet
Number of subjects: 119

Group type: COMPARATOR
Intervention: Interventions targeting physical activity
Number of subjects: 119

Group type: COMPARATOR
Intervention: Interventions targeting media use
Number of subjects: 119

Group type: COMPARATOR
Intervention: Interventions implemented in clinics
Number of subjects: 119

Group type: COMPARATOR
Intervention: Interventions implemented in home-based settings
Number of subjects: 119

Group type: COMPARATOR
Intervention: Interventions conducted in the United States
Number of subjects: 119

Group type: COMPARATOR
Intervention: Randomized controlled design
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Education on sleep hygiene
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Responsive feeding practices
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Limiting media use
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Bedtime routines
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Measurement of children's sleep by parent report
Number of subjects: 119
Study: 27009831

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60 mg once daily plus Asunaprevir (ASV) 100 mg twice daily for 12 weeks
Number of subjects: 186
Study: 24677417

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ischaemic muscle pain (ISC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conditioning stimulus (CPT or ISC)
Number of subjects: 25
Study: 22580860

Group type: EXPERIMENTAL
Intervention: IV fentanyl PCA after SA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IV fentanyl PCA after GA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IV tramadol PCA after GA
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 20542780

Group type: EXPERIMENTAL
Intervention: FX06
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 18583470

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg by mouth daily
Number of subjects: 27
Study: 16525672

Group type: EXPERIMENTAL
Intervention: Protein-bound polysaccharide K (PSK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12705565

Group type: EXPERIMENTAL
Intervention: Sleep restriction (1 hour less sleep)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sleep extension (1 hour more sleep)
Number of subjects: 77
Study: 10871461

Group type: EXPERIMENTAL
Intervention: Standard assay for activated protein C resistance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Modified assay for activated protein C resistance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pregnancies of women with preexisting activated protein C resistance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Allele-specific polymerase chain reaction analysis
Number of subjects: 20
Study: 8706037

Group type: EXPERIMENTAL
Intervention: Number of live births
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptoms in the breast revealed on direct questioning
Number of subjects: 0
Study: 1550275

Group type: EXPERIMENTAL
Intervention: 1 ml propofol (10 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1 ml placebo (Intralipid)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Supplementary dose of 10 mg propofol (for treatment failures in placebo group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propofol group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 3897722

Group type: EXPERIMENTAL
Intervention: 330 mg of acetylsalicylic acid (aspirin) plus 75 mg of dipyridamole three times daily
Number of subjects: 125
Study: 30838188

Group type: EXPERIMENTAL
Intervention: Blindfold group (BG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 48
Study: 29303446

Group type: EXPERIMENTAL
Intervention: Concurrent ipilimumab
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Concurrent ipilimumab with SRS dose ≥ 20 Gy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Any ipilimumab
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no ipilimumab)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall incidence of pathologically confirmed radiation necrosis (RN)
Number of subjects: 72
Study: 26880541

Group type: EXPERIMENTAL
Intervention: Decision support intervention (multimodal including counselling by a trained nurse)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard decision-making support (control group)
Number of subjects: 0
Study: 25189328

Group type: EXPERIMENTAL
Intervention: Educational programme based on the Health Belief Model (HBM), consisting of four 1-hour sessions twice per week
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study: 23181955

Group type: EXPERIMENTAL
Intervention: Yang-style Tai Chi exercise programme (3 times a week for 8 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 58
Study: 19147137

Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PID patients with myeloperoxidase G/A alleles
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PID patients with G/G homozygous alleles
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study: 18476391

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ferrous sulphate tablet 100 mg (Control)
Number of subjects: 60
Study: 15650846

Group type: EXPERIMENTAL
Intervention: Ziprasidone (IM up to 3 days, then oral 40-80 mg, b.i.d.)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Haloperidol (IM up to 3 days, then oral 5-20 mg/day)
Number of subjects: 565
Study: 12105288

Group type: EXPERIMENTAL
Intervention: Weight Watchers program
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Individualized approach
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Comprehensive group (individualized counseling + Weight Watchers)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 10431068

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: All groups (including physical exercise, dobutamine, dipyridamole, ATP)
Number of subjects: 40
Study: 7552502

Group type: EXPERIMENTAL
Intervention: IDUs enrolled in the HIV vaccine trial
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Follow-up visits for IDUs
Number of subjects: 119
Study: 2349198

Group type: EXPERIMENTAL
Intervention: Nebulised fenoterol (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebulised terbutaline (5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 387495

Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone dipropionate cream
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0.025% fluocinolone acetonide cream
Number of subjects: 62
Study: 31714121

Group type: EXPERIMENTAL
Intervention: Afrikaans language communication skills classes
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Xhosa language communication skills classes
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Second language learning
Number of subjects: 600
Study: 28482738

Group type: EXPERIMENTAL
Intervention: DMARD + Adalimumab (ADA), n = 42
Number of subjects: 80

Group type: COMPARATOR
Intervention: DMARD + Placebo (PLA), n = 38
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy Volunteers (HV), n = 40
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall RA patients (DMARD + ADA and DMARD + PLA)
Number of subjects: 80
Study: 25562265

Group type: EXPERIMENTAL
Intervention: Intensive therapy (n=711) aimed at achieving glycemia as close to the nondiabetic range as safely possible.
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional therapy (n=730) with the goal of avoiding symptomatic hypoglycemia and hyperglycemia.
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Higher levels of glycated hemoglobin (HbA1c)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Development of albuminuria
Number of subjects: 1441
Study: 23631512

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ampicillin-Sulbactam (Unasyn)
Number of subjects: 142
Study: 21991730

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg kg(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 19023657

Group type: EXPERIMENTAL
Intervention: Project MYTRI intervention activities (peer-led classroom activities involving games, competitions, etc.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Project MYTRI intervention activities
Number of subjects: 0
Study: 16960411

Group type: EXPERIMENTAL
Intervention: Carvedilol therapy (6.25 mg/day uptitrated to 23.9 +/- 13.9 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (14 patients, mean age 69.4 years, unable to take carvedilol)
Number of subjects: 31
Study: 12670065

Group type: EXPERIMENTAL
Intervention: At-home treatment with 10% carbamide peroxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-office treatment with 35% hydrogen peroxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: At-home treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-office treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 10968244

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin and iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9366101

Group type: EXPERIMENTAL
Intervention: Nicergoline
Number of subjects: 131

Group type: COMPARATOR
Intervention: Naftidrofuryl
Number of subjects: 131
Study: 1555086

Group type: EXPERIMENTAL
Intervention: alpha‐ketoisocaproate (17 g day‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: branched chain solution (3.3 g nitrogen day‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: balanced amino acid solution (no further supplements)
Number of subjects: 24
Study: 3104657

Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms nocte
Number of subjects: 203

Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte
Number of subjects: 203
Study: 30769358

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 31272834

Group type: EXPERIMENTAL
Intervention: Mokuboito plus standard therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 40
Study: 28877862

Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention with virtual assistants
Number of subjects: 8062

Group type: COMPARATOR
Intervention: Control group (standard information)
Number of subjects: 8062
Study: 26301603

Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive treatment (n=199)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Continuation of antihypertensive treatment (n=186)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive treatment
Number of subjects: 385
Study: 23839180

Group type: EXPERIMENTAL
Intervention: Duac® Gel (BPO 5%‐clindamycin phosphate 1.2%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acanya® Gel (BPO 2.5%‐clindamycin phosphate 1.2%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aczone® Gel (dapsone 5%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epiduo® Gel (BPO 2.5%‐adapalene 0.1%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 0
Study: 21631510

Group type: EXPERIMENTAL
Intervention: CAF + EMD
Number of subjects: 12

Group type: COMPARATOR
Intervention: CAF + CTG
Number of subjects: 12
Study: 19538082

Group type: EXPERIMENTAL
Intervention: Systems Training for Emotional Predictability and Problem Solving (STEPPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BEST scale
Number of subjects: 0
Study: 16440121

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline plus intravenous betamethasone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nebulized terbutaline alone (control)
Number of subjects: 22
Study: 15571785

Group type: EXPERIMENTAL
Intervention: Family-focused psychoeducational treatment for bipolar adolescents (FFT-A) combined with mood stabilizing medications
Number of subjects: 20
Study: 11810324

Group type: EXPERIMENTAL
Intervention: Harpagophytum extract LI 174 (Rivoltan(R)) 2x480 mg/day for 4 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 9020324

Group type: EXPERIMENTAL
Intervention: Enteric drainage (ED)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bladder drainage (BD)
Number of subjects: 46
Study: 7885976

Group type: EXPERIMENTAL
Intervention: Increased contact with pharmacists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual pharmacy care with minimum contact
Number of subjects: 0
Study: 3257749

Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone phosphate, topically applied four times a day for 7 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo, topically applied to contralateral eye
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparison between dexamethasone and placebo
Number of subjects: 13
Study: 31379271

Group type: COMPARATOR
Intervention: Smile Connect (SC) programme for older adults; twelve 30-minute chat sessions conducted via Skype over six weeks.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Smile Connect (SC) programme for young adults; twelve 30-minute chat sessions conducted via Skype over six weeks.
Number of subjects: 94
Study: 29311137

Group type: EXPERIMENTAL
Intervention: AZD7325 (4‐amino‐8‐(2‐fluoro‐6‐methoxyphenyl)‐N‐propylcinnoline‐3‐carboxamide) administered orally, repeated doses over a period not specified.
Number of subjects: 0
Study: 26667151

Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 25342205

Group type: EXPERIMENTAL
Intervention: DEX 1.0 µg/kg 5 min before propofol injection (group VII)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (isotonic saline, group I)
Number of subjects: 210
Study: 23329121

Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 66% of the individual electrically stimulated phosphene threshold
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 150% of the individual electrically stimulated phosphene threshold
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation (0% stimulation)
Number of subjects: 12
Study: 22145513

Group type: EXPERIMENTAL
Intervention: Ramtace 10 mg (test product)
Number of subjects: 24
Study: 19828901

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Weight loss at month-6
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Higher baseline BMI
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Less weight loss at month-6
Number of subjects: 322
Study: 16289360

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pregnant women with EPDS scores >9 points (maternal depression)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-pregnant women (control group)
Number of subjects: 80
Study: 14767603

Group type: EXPERIMENTAL
Intervention: Epidural fat interposition between the dura mater and spinous process of L5
Number of subjects: 178

Group type: COMPARATOR
Intervention: No epidural fat interposition (Control group)
Number of subjects: 178
Study: 10981566

Group type: EXPERIMENTAL
Intervention: 0.5 microg/ml sufentanil
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: 0.75 microg/ml sufentanil
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: 1 microg/ml sufentanil
Number of subjects: 243
Study: 9024262

Group type: EXPERIMENTAL
Intervention: Ovine CRH (oCRH) injection during desmopressin (DP) infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ovine CRH (oCRH) injection during saline (SAL) infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Desmopressin (DP) infusion plus SAL injection
Number of subjects: 6

Group type: COMPARATOR
Intervention: SAL injection during SAL infusion
Number of subjects: 6
Study: 8453023

Group type: EXPERIMENTAL
Intervention: Dolasetron administered orally at doses ranging from 50 to 400 mg (mesylate monohydrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced dolasetron metabolite
Number of subjects: 0
Study: 3142400

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both drugs (at D 90)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 29320595

Group type: EXPERIMENTAL
Intervention: 1060 nm laser treatment
Number of subjects: 35
Study: 27177041

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 100
Study: 25716899

Group type: EXPERIMENTAL
Intervention: SCORES intervention
Number of subjects: 460